Feb. 9, 2022, BEIJING & SHANGHAI & CAMBRIDGE, Mass. – EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, and Neukio Biotherapeutics, a biotechnology company focused on the development and commercialization of allogenic iPSC-CAR-NK cell therapies, today announced an R&D collaboration to develop next-generation immune cell therapies. [Read more…]
Cultured Meat Market: From the Lab to the Grocery Store
Cultured meat refers to lab-grown meat created using cell culture techniques. It is produced by growing master cells collected from cattle, chicken, pigs, fish, and lamb, as well as other types of livestock and seafood. In addition to meat and seafood production, cultured meat techniques can be used to ethically manufacture other types of animal products, such as leather, fur, milk, and hen-free egg whites, for example. Cultured meat is ethically produced, because livestock is not used within the manufacturing processes beyond collecting the initial cells for culture. [Read more…]
I Peace’s Cell Manufacturing Facility “Peace Engine Kyoto” now registered as U.S. FDA Drug Establishment
Palo Alto, California, January 25, 2022 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up, announced that its cell manufacturing facility is now listed on the FDA “Drug Establishments Current Registration Site.” The registration recognizes I Peace’s cell manufacturing facility as suitable for drug manufacturing, based on detailed information submitted to the FDA. Comprehensive details of clinical grade iPSC manufacturing are registered in the FDA Drug Master File (DMF). [Read more…]
Onk Therapeutics Secures $21.5M Series A for Cord Blood and iPSC-derived NK Cell therapies
-
$21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
-
Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
-
Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability
Breakthrough Solutions for Human Primary Cells & Hematologic Tissue Products
AllCells is a biotechnology company that specializes in biologically relevant, high quality primary cells to enable drug discovery, development, and manufacturing of cell therapies. Leveraging its expertise in hematological and immune cell isolations, combined with on-site whole blood and bone marrow tissue collection operations, AllCells maintains one of the world’s largest and most diverse repositories of donor profiles that can be screened and qualified for biomedical applications.
I had the honor of interviewing Dr. Jay Tong, President and CEO of AllCells. In this interview, we discuss AllCells history, its leadership in blood donor cell collections and hematologic tissue products and the recent opening of its newest facility in Boston, Massachusetts. We also explore the company’s long-term goals and expansion into the cell therapy development space. [Read more…]
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 202
- Next Page »